LH031 / 4SC, Link Health Group - LARVOL DELTA

The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. (PubMed, Clin Transl Med) - No abstract available

Journal • Neuroblastoma • Oncology • Solid Tumor • KIF11

[VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC (EACR 2021) - "The aim of our study is to investigate the role of KIF11, protein essential during mitosis, in the development of CRPC and therapy resistance and to evaluate its potential as a therapeutic target using 4SC-205, a novel KIF11 inhibitor Material and Methods KIF11 expression was studied using PCa databases and further validated in PCa cell lines and patient tissue samples by western blot and immunohistochemistry respectively. These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the..."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • KIF11

[VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC (EACR 2021) - "The aim of our study is to investigate the role of KIF11, protein essential during mitosis, in the development of CRPC and therapy resistance and to evaluate its potential as a therapeutic target using 4SC-205, a novel KIF11 inhibitor Material and Methods KIF11 expression was studied using PCa databases and further validated in PCa cell lines and patient tissue samples by western blot and immunohistochemistry respectively. These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the..."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • KIF11

[VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC (EACR 2021) - "The aim of our study is to investigate the role of KIF11, protein essential during mitosis, in the development of CRPC and therapy resistance and to evaluate its potential as a therapeutic target using 4SC-205, a novel KIF11 inhibitor Material and Methods KIF11 expression was studied using PCa databases and further validated in PCa cell lines and patient tissue samples by western blot and immunohistochemistry respectively. These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the..."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • KIF11

[VIRTUAL] KIF11-AR dual inhibition: a novel strategy to reverse endocrine therapy resistance in CRPC (EACR 2021) - "The aim of our study is to investigate the role of KIF11, protein essential during mitosis, in the development of CRPC and therapy resistance and to evaluate its potential as a therapeutic target using 4SC-205, a novel KIF11 inhibitor Material and Methods KIF11 expression was studied using PCa databases and further validated in PCa cell lines and patient tissue samples by western blot and immunohistochemistry respectively. These led us to hypothesize that KIF11 and the AR form a positive feedback loop in PCa promoting cell proliferation, the development of CRPC and therapy resistance. Furthermore, we demonstrate that KIF11 inhibition effectively enhances the sensitivity of CRPC cells and reverses enzalutamide resistance both, in vitro and in vivo Conclusion Altogether, we conclude that KIF11 overexpression plays an important role in the progression of CRPC and therapy resistance and we propose that a dual inhibition of the AR pathway and KIF11 could enhance the..."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • KIF11

[VIRTUAL] A Phase 1 Dose-Escalation Study of LH031, a Kinesin Spindle Protein Inhibitor, in Patients with Refractory/Resistance Multiple Myeloma (ASH 2020) - "The current phase 1 study showed that LH031 was an accepted safety profile at 20mg. DLTs was expected and reversible. MTD is to be determined by recruiting 3 more subjects at 20mg dose."

Clinical • P1 data • Hematological Disorders • Hematological Malignancies • Leukopenia • Multiple Myeloma • Neutropenia • Oncology

4SC AG receives milestone payment from Link Health – Link Health initiates phase I clinical study of LH031 (4SC-205) in advanced solid malignancies or lymphoma (4SC Press Release) - "4SC AG...announced, that it received a single digit million Euro milestone payment from its partner Guangzhou Link Health Pharma Co., Ltd (Link Health) in accordance with the licensing and development agreement for the cancer therapeutic candidate 4SC-205."

Financing